Mechanism of inhibitory effect of glycyrrhizin on replication of human immunodeficiency virus (HIV). NLM AIDSLINE Important note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Mechanism of inhibitory effect of glycyrrhizin on replication of human immunodeficiency virus (HIV).

Antiviral Res. 1988 Dec 11;10(6):289-98. Unique Identifier : AIDSLINE MED/89271834
Ito M; Sato A; Hirabayashi K; Tanabe F; Shigeta S; Baba M; De Clercq E; Nakashima H; Yamamoto N; Department of Bacteriology, Fukushima Medical College, Japan.

Abstract: Glycyrrhizin (GL) achieved a dose-dependent inhibition of the replication of human immunodeficiency virus type 1 (HIV-1) in MOLT-4 (clone No. 8) cells within the concentration range of 0.075 to 0.6 mM. Within this concentration range, GL also effected a dose-dependent reduction in the protein kinase C (PKC) activity of MOLT-4 (clone No. 8) cells. A well-known PKC inhibitor, 1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride (H-7), also proved inhibitory to HIV-1 replication in MOLT-4 (clone No. 8) cells. PKC inhibition may thus be considered as one of the mechanisms by which GL inhibits HIV-1 replication. In addition, GL may also owe its anti-HIV-1 activity, at least in part, to an interference with virus-cell binding, since the compound at 1.2 mM partially inhibited the adsorption of radiolabeled HIV-1 particles to MT-4 cells. At this concentration GL also suppressed giant cell formation induced by co-culturing MOLT-4 (clone No. 8) cells with MOLT-4/HTLV-IIIB cells, whereas the PKC inhibitor H-7 failed to do so.
Keywords: Adsorption Antiviral Agents/*PHARMACOLOGY Clone Cells Cytopathogenic Effect, Viral Dose-Response Relationship, Drug Glycyrrhetinic Acid/*ANALOGS & DERIVATIVES/PHARMACOLOGY Human HIV Antigens/BIOSYNTHESIS HIV-1/*DRUG EFFECTS/PHYSIOLOGY Protein Kinase C/*ANTAGONISTS & INHIB Virus Replication/DRUG EFFECTS JOURNAL ARTICLE

KWDadsorptionantiviralagents/KWDpharmacologyclonecellscytopathogeniceffect,viraldose-responserelationship,drugglycyrrhetinicacid/KWDanalogs&derivatives/pharmacologyhumanhivantigens/biosynthesishiv-1/KWDdrugeffects/physiologyproteinkinasec/KWDantagonists&inhibvirusreplication/drugeffectsjournalarticle
890930
M8990781

Copyright © 1989 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1989. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1989. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .